Frizzled 2 (FZD2) Human shRNA Plasmid Kit (Locus ID 2535)
CAT#: TR312884
FZD2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 5 publications. |
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | Frizzled 2 (FZD2) Human shRNA Plasmid Kit (Locus ID 2535) |
Locus ID | 2535 |
UniProt ID | Q14332 |
Synonyms | fz-2; Fz2; fzE2; hFz2; OMOD2 |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | FZD2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 2535). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001466, NM_001466.1, NM_001466.2, NM_001466.3, BC052266, BC113402, BC113404, NM_001466.4 |
Summary | This intronless gene is a member of the frizzled gene family. Members of this family encode seven-transmembrane domain proteins that are receptors for the wingless type MMTV integration site family of signaling proteins. This gene encodes a protein that is coupled to the beta-catenin canonical signaling pathway. Competition between the wingless-type MMTV integration site family, member 3A and wingless-type MMTV integration site family, member 5A gene products for binding of this protein is thought to regulate the beta-catenin-dependent and -independent pathways. [provided by RefSeq, Dec 2010] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (5)
The use of this RNAi has been cited in the following citations: |
---|
Suppression of hepatocellular carcinoma cell proliferation by short hairpin RNA of frizzled 2 with Sonazoid-enhanced irradiation
,Tomizawa, M;Shinozaki, F;Motoyoshi, Y;Sugiyama, T;Yamamoto, S;Ishige, N;,
Int. J. Oncol.
,PubMed ID 26648389
[FZD2]
|
Gastric cancer cell proliferation is suppressed by frizzled-2 short hairpin RNA
,Tomizawa, M;Shinozaki, F;Motoyoshi, Y;Sugiyama, T;Yamamoto, S;Ishige, N;,
Int. J. Oncol.
,PubMed ID 25586465
[FZD2]
|
Short hairpin RNA of frizzled-2 suppresses the proliferation of hepatocellular carcinoma cells
,Tomizawa, M;Shinozaki, F;Motoyoshi, Y;,
ONCOLOGY LETTERS
[FZD2]
|
Frizzled-2: A potential novel target for molecular pancreatic cancer therapy
,Tomizawa, M;Shinozaki, F;Sugiyama, T;,
Oncology Letters 74
,PubMed ID 24348824
[FZD2]
|
Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer
,John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan, Anna Spreafico, Todd M. Pitts, M. Pia Morelli, Heather M. Selby, Maria I. Kachaeva, Sara A. Flanigan, Gillian N. Kulikowski, Stephen Leong, John J. Arcaroli, Wells A. Messersmith, and S. Gail Eckhardt,
Mol. Cancer Ther., Dec 2010; 9: 3351 - 3362
[FZD2]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...